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Abstract
Background:  The molecular mechanisms that govern stem cell differentiation along the
endothelial lineage remain largely unknown. Ets related gene (ERG) has recently been shown to
participate in the transcriptional regulation of a number of endothelial specific genes including VE-
cadherin (CD144), endoglin, and von Willebrand's Factor (vWF). The specific role of the ETS factor
ERG during endothelial differentiation has not been evaluated.
Results: ERG expression and function were evaluated during the differentiation of embryonic stem
cells into embryoid bodies (EB). The results of our study demonstrate that ERG is first expressed
in a subpopulation of vascular endothelial growth factor receptor 2 (VEGF-R2) expressing cells that
also express VE-cadherin. During ES cell differentiation, ERG expression remains restricted to cells
of the endothelial lineage that eventually coalesce into primitive vascular structures within
embryoid bodies. ERG also exhibits an endothelial cell (EC)-restricted pattern during
embryogenesis. To further define the role of ERG during ES cell differentiation, we used a
knockdown strategy to inhibit ERG expression. Delivery of three independent shRNA led to 70-
85% reductions in ERG expression during ES cell differentiation compared to no change with
control shRNA. ERG knockdown was associated with a marked reduction in the number of ECs,
the expression of EC-restricted genes, and the formation of vascular structures.
Conclusion: The ETS factor ERG appears to be a critical regulator of EC differentiation.
Background
Vasculogenesis, the development of the primary vascula-
ture during embryogenesis, requires a highly orchestrated
series of events that are spatially and temporally regulated
[1]. Intra-embryonic vasculogenesis is preceded by extra-
embryonic vascular development within the yolk sac [2].
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Pioneering studies conducted in avian embryos and sub-
sequently extended in amphibian and mammalian model
systems in multiple different species have demonstrated
the close association between the development of the
hematopoietic and endothelial lineages [3].
The hemangioblast is a bipotent cell of mesodermal ori-
gin that can give rise to hematopoietic and ECs. The pos-
sible existence of a common precursor was originally
suggested because of the close spatial association of
hematopoietic cells and ECs in the blood islands associ-
ated with the developing embryos, and also because
hematopoietic and ECs co-express a number of genes.
One of the earliest markers expressed on cells of endothe-
lial and hematopoietic origin is the VEGF receptor Flk-1 or
VEGF-R2. Further support for the existence of the heman-
gioblast comes from the differentiation of embryonic
stem cells along the endothelial and hematopoietic line-
ages [4,5]. When individual cells are allowed to differenti-
ate further, they form adherent cells that express more
endothelial specific markers whereas many of the non-
adherent cells, presumed to be of hematopoietic origin,
express such genes as β-hemoglobin [6]. Differentiation
along the hematopoietic lineage is marked by the expres-
sion of cell surface markers including CD41 and CD45. A
similar, time-dependent change in the expression of cell
surface markers on cells of the hematopoietic and
endothelial lineage occurs during the differentiation of
embryonic stem cells into embryoid bodies.
Several receptor tyrosine kinases, including the VEGF-R2,
VEGF-R1, Tie1, and Tie2 genes are known to be critical
mediators of endothelial differentiation and vascular
development. Targeted disruption of any of these genes
leads to defects in vascular development and early embry-
onic lethality [7-9]. Comparison of the mouse and human
DNA sequences within the regulatory regions of these
genes has facilitated the identification of conserved bind-
ing sites for different classes of transcription factors. The
Tie1 gene promoter contains conserved binding sites for
ETS factors and AP2 [10]. Mutations in most of these con-
served binding sites leads to marked reductions in the
ability of the Tie1 promoter to direct LacZ gene expression
in transgenic animals. A similar approach has been used
to identify conserved binding sites for the ETS factors,
SCL/tal-1, and GATA factors in the VEGF-R2 gene. Point
mutations in some of these binding sites also leads to
marked reductions in the vascular specific expression
directed by the VEGF-R2 regulatory regions in transgenic
studies [11]. Conserved ETS binding sites exist in the Tie2
and VEGF-R1 genes [12,13]. The results of these studies
strongly support the hypothesis that members of certain
transcription factor families, including the ETS and GATA
transcription factor families are involved in regulating the
different stages of vascular development and endothelial
differentiation by regulating endothelial-specific gene
expression.
The ETS genes are a family of at least thirty members that
function as transcription factors. All ETS factors share a
highly conserved 80-90 amino acid long DNA binding
domain, the ETS domain [14]. Many macrophage, B cell
and T cell specific genes are regulated by ETS factors. More
recently several vascular-specific genes have been shown
to be downstream targets of selected ETS factors. In addi-
tion to the Tie1, Tie2, VEGF-R1, and VEGF-R2 genes men-
tioned above, several other endothelial specific genes
including von Willebrand Factor (vWF), PECAM-1, VE-
cadherin, endothelial nitric oxide synthase genes have
functionally important conserved binding sites for mem-
bers of the ETS transcription factor family [15-18]. The
ETS factor ERG has recently been shown to interact with a
number of other transcription factors to regulate several
endothelial-specific genes including angiopoietin-2, VE-
cadherin, endoglin, and vWF [17-20]. The goal of this
study was to determine the role of ERG as a transcriptional
regulator of ES cell differentiation, and in particular, to
determine whether it plays a role in regulating EC differ-
entiation or hematopoiesis.
Results
ERG expression during endothelial differentiation
We recently completed a gene profiling study comparing
the expression of genes in VEGF-R2 expressing embryonic
stem cells as they differentiate along the endothelial ver-
sus the hematopoietic lineages. Of particular interest to us
was the ETS factor ERG which was restricted to VE-cad-
herin positive cells[21]. We analyzed ERG expression fur-
ther during ES cells differentiation by quantitative (Q)-
RT-PCR and observed a very similar temporal pattern for
the expression of ERG and VE-cadherin (Figure 1A). Fluo-
rescence activated cell sorting (FACS) was used to further
define the specific populations of cells expressing ERG
during ES cell differentiation. Cells expressing either
VEGF-R2 (day 3.5), the endothelial-specific marker VE-
cadherin (day 4.5), or the hematopoietic marker CD41
(day 4.5) were sorted and RNA was extracted from these
cells. Q-RT-PCR demonstrated that ERG was expressed in
VEGF-R2 positive cells at day 3.5 and then in VE-cadherin
positive cells, but not CD41 expressing cells at day 4,5
(Figure 1B). Flow cytometry using an antibody directed
against ERG demonstrated a time-dependent increase in
ERG expression during differentiation with approximately
13.5% of cells expressing ERG by day 10 (Figure 1C). ERG
segregation with specific cell populations (i.e. hematopoi-
etic and/or endothelial) was evaluated at day 8.5 by flow
cytometry using antibodies directed against ERG and one
of the following: VE-cadherin, CD41 and the erythroid
marker Ter119. ERG is predominantly expressed in VE-
cadherin positive cells, and not CD41 or Ter119 positiveBMC Developmental Biology 2009, 9:72 http://www.biomedcentral.com/1471-213X/9/72
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cells (Figure 1D). Although only a small percentage of
cells express Ter119 at day 8.5, ERG was not expressed in
Ter119 expressing cells at later time points either (Addi-
tional file 1).
Evaluation of temporal and spatial expression of ERG 
during ES cell differentiation
ERG and VE-cadherin expression were evaluated in frozen
EB sections at day 3-10 by immunofluorescence to define
the temporal and spatial pattern of ERG expression in
developing EBs. ERG and VE-cadherin are first expressed
at day 3 to 4, and there is a very close association between
cells expressing ERG (green) and those expressing VE-cad-
herin (red) throughout EB differentiation (Figure 2A, 2B).
Whereas ERG appears to be predominantly restricted to
the nucleus of cells, VE-cadherin is observed on the cell
surface. Furthermore, VE-cadherin expressing cells coa-
lesce into structures resembling primitive blood vessels
ERG expression in differentiating EBs is endothelial-cell specific Figure 1
ERG expression in differentiating EBs is endothelial-cell specific. (A) Quantitative RT-PCR of RNA derived from EBs 
at different stages of differentiation (days 0-10), showing temporal correlation in the expression of ERG (blue) and endothelial-
specific VE-cadherin (purple). Copy numbers (normalized per 10,000 copies GAPDH) are shown for VE-cadherin (left) and 
ERG (right) Y-axis. (n = 3) (B) ERG expression in sorted cell populations. Q-RT-PCR analysis of RNA isolated from EB cells 
sorted for VEGF-R2 at day 3.5, and VE-cadherin and CD41 at day 4.5 are shown. ERG is present in the mesodermal/heman-
gioblast cells expressing VEGF-R2 at day 3.5. ERG is highly enriched in the VE-cadherin expression population, but is almost 
absent in the CD41+ cells at day 4.5. Error bars indicate means +/- S.D. (n = 3)(C) Flow cytometry analysis of ERG expression 
in EBs at different time points of ES cell differentiation. The increasing percentage of cells expressing ERG over time is shown 
by the shifting cell population (green) along the x-axis, compared to the ERG negative cells, shown in red. (D) Flow cytometry 
analysis of ERG expression in relation to other cell-lineage specific markers: hematopoietic (CD41 and Ter119), and endothe-
lial (VE-cadherin) in day 8.5 EBs. Cell population expressing ERG was labeled with green fluorescent marker (FITC) and 
migrated along the x-axis.
Day 4  Day 8  Day 6  Day 10 
0.5 %  3.3 %  6.7 %  13.5 % 
FITC isotype 
0
200
400
600
800
1000
1200
1400
Flk-1 D3.5 VE-cadherin
D4.5
CD41 D4.5 
M
o
l
e
c
u
l
e
 
c
o
u
n
t
s
/
G
A
P
D
H
 
n
o
r
m
a
l
i
z
e
d
 
FITC-isotype 
P
E
-
i
s
o
t
y
p
e
 
C
D
4
1
 
T
e
r
1
1
9
 
V
E
-
c
a
d
h
e
r
i
n
 
ERG-FITC 
0.5 %  9.5 % 
8.0 %  9.4 % 
 1.5 %  0 %  9.2 %  0.6 % 
2.6 % 
A B
D
C
ERG-FITC BMC Developmental Biology 2009, 9:72 http://www.biomedcentral.com/1471-213X/9/72
Page 4 of 14
(page number not for citation purposes)
and line the inner surface of the cystic structures (Figure
2C, 2D). Further demonstration of the close association
between the VE-cadherin expressing cells and ERG was
observed by confocal microscopy also demonstrating the
nuclear localization of ERG (Additional file 2). A similar
close association between ERG and another EC-restricted
protein endoglin (CD105) was also observed during ES
cell differentiation (Additional file 3), but that was dis-
tinct from the hematopoietic marker CD45.
ERG expression during vascular development
To begin to define ERG expression during vascular devel-
opment, mouse embryos at different stages of develop-
ment were isolated. ERG expression was evaluated by
immuno-fluorescence. As early as E7.5 ERG and VEGF-R2
appear to be expressed in the blood islands enriched in
hemangioblasts that are the common early precursors for
the endothelial and hematopoietic lineages. Serial sec-
tions of yolk sac demonstrate expression of ERG and
VEGF-R2 in the same region (Additional file 4). Later dur-
ing development, we observed a close correlation between
ERG and VE-cadherin expression in developing vascular
structures and blood vessels in a number of tissues. For
example, ERG expression is observed in ECs of the dorsal
aorta at embryonic day 9.5 (Figure 3A), and at day 12.5
(Figure 3B). Although there is faint ERG staining in a few
Temporal and spatial ERG expression pattern in differentiating ES cells Figure 2
Temporal and spatial ERG expression pattern in differentiating ES cells. (A) Fluorescence immunostaining of frozen 
EB sections with rabbit anti-ERG and Alexa 498 anti-rabbit IgG (green) at the early stages of EB differentiation. ERG is first 
detected in the developing EBs at day 3. (B) Double immunostaining of frozen EB sections with ERG Ab (green) and VE-cad-
herin Ab (red) shows consistent co-localization of the two markers during the time-course of EB differentiation. DAPI nuclear 
staining (shown in blue) provides an outline of the general EB morphology. (C) Fluorescence immunostaining of frozen EB sec-
tions with anti-ERG Ab (green) at later stages of EB differentiation (days 6, 8, and 10) demonstrates ERG expression and organ-
ization in more complex vascular structures lining the walls of the vascular channels. (D) Co-expression of ERG (green) and 
VE-cadherin (red) in the vascular channels of day 10 EB. DAPI nuclear staining (blue) provides an outline of the general EB mor-
phology. The images were obtained with Leica fluorescence microscope at 40× magnification. Scale bar represents 200 μm.BMC Developmental Biology 2009, 9:72 http://www.biomedcentral.com/1471-213X/9/72
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cells within the lumen of the aorta, the vast majority of
ERG staining is located within the vessel wall in close
approximation with VE-cadherin. Just as in the EBs, ERG
expression is localized within the nucleus of VE-cadherin
expressing cells. ERG expression is also observed in the
trabeculated endocardial surface of the common atrium
and ventricle of the heart at embryonic stage E9.5 (Figure
4). EC-specific expression was also observed in several
other tissues including the intersomitic, and mesonephric
blood vessels of the aorta-gonado-mesonephros (AGM)
region, and blood vessels of the umbilical cord (Addi-
tional files 5, 6, and 7).
Lentiviral knockdown of ERG in ES cells
To further define the role of ERG as a transcriptional reg-
ulator of endothelial-specific gene expression and
endothelial differentiation, we tested the ability of four
different lentiviral vectors encoding shRNA directed
against mouse ERG to suppress ERG expression during ES
cell differentiation. Sequence analysis of the shRNA
sequences confirmed the specificity for ERG (with no sig-
nificant sequence homology to other ETS family mem-
bers). Undifferentiated murine CCE ES cells were infected
with control (scrambled shRNA) and the four lentiviral
vectors directed against ERG (Figure 5A). Puromycin was
used to stably select individual clones. ERG expression
was measured in the clones 8 days after their differentia-
tion into EBs. A 75-80% reduction in ERG expression was
observed in three out of the four ERG shRNA (clones 2, 3,
and 4), as measured by Q-RT-PCR and Western blot anal-
ysis when compared to control shRNA (Figure 5B and
5C). To evaluate whether changes in ERG expression are
associated with alterations in the number of ECs and/or
vascular structure formation, we examined the expression
of ERG and VE-cadherin in the ERG shRNA clones.
Whereas the control shRNA clones exhibited a similar pat-
tern of vascular structure formation to untransfected ES
cells during EB formation, there was a marked reduction
in the number of VE-cadherin expressing cells and the for-
mation of vascular structures in the ERG shRNA clones
(Figure 5D). Because we first observed ERG expression in
a subset of VEGF-R2 expressing cells, we also wanted to
determine whether ERG affects the number of VEGF-R2
expressing cells or hemangioblast development. VEGF-R2
expression was evaluated in two of the ERG knockdown
clones compared to the control clones. There was no
change in the number of VEGF-R2 expressing cells at day
3 (Figure 5E), suggesting that ERG does not regulate
hemangioblast development, but rather the very early
stages of EC differentiation. At later time points (day 6),
the number of VEGF-R2 positive cells decreases in ERG
shRNA EBs as compared to controls which is most likely
due to the decreased number of EC progenitors or ECs
expressing VEGF-R2 (Figure 5E).
Flow cytometric evaluation of ERG and control shRNA 
treated ES cells
To evaluate the effect of ERG suppression on endothelial
and hematopoietic lineages, flow cytometric analysis
using markers specific for both lineages was performed on
day 6, 8 and 10 of differentiation. A reduction in several
genes expressed on endothelial cells was observed in the
ERGshRNA clones compared to the controls, with the
most striking reductions in the direct targets of ERG VE-
Cadherin and endoglin, particularly at day 10 (Table 1
and Additional file 8) [19,22]. It is known that some of
these genes, such as endoglin are expressed on the heman-
gioblast cells as well as endothelial cells [23]. In a separate
experiment using shRNA knockdown of ERG in HUVECS
cells, we identified that Tie2 and VEGF-R1 (Flt-1) are not
direct targets of ERG (data not shown). However, a signif-
icant reduction of Tie2 and VEGF-R1 was seen in our ERG-
shRNA clones by FACS analysis, indicating that
suppression of ERG affects not only the expression of ERG
target genes but also the number of ECs. In contrast, no
change in the expression of CD41 and CD45 occurred
suggesting that there was no significant effect on hemat-
opoietic lineage differentiation (Table 1). Furthermore,
we observed a decrease of about 30% in the potential of
the ERGshRNA clones to form vascular sprouts when
compared to the controls (Additional file 9). This may be
related to a decrease in the number of ECs and/or
impaired function of the ECs due the reduction in the
expression of several endothelial-restricted genes. We also
evaluated the ability of control and ERGshRNA ES cells to
form hematopoietic cells using a blast colony-forming cell
assay. No difference was observed in the hematopoietic
potential of control versus ERGshRNA ES cells (Addi-
tional file 10).
Identification of ERG downstream targets during ES cell
differentiation
Previous studies have shown that targeted disruption or
knockdown of VE-cadherin alone is not sufficient to
inhibit EC differentiation [24]. To further define the
molecular mechanisms by which ERG regulates EC differ-
entiation, we sorted VEGF-R2 expressing cells after 2, 3,
and 4 days of differentiation using mouse ES cells with
stable suppression of ERG and from control cells. ERG
expression was nearly undetectable at day 2 (Figure 6A).
Early expression was detected at day 3 and significant
reductions of ERG expression were observed in the ERG
shRNA cells at both day 3 and day 4. Comparison of ERG
shRNA and control shRNA cells at day 3 and day 4
revealed several genes that were differentially expressed
(LCB >1.5). Most of the genes were repressed upon ERG
suppression. The heat map of a selected number of differ-
entially downregulated genes at day 3 and 4 are shown
(Figure 6B and Additional file 11). We observed reduc-BMC Developmental Biology 2009, 9:72 http://www.biomedcentral.com/1471-213X/9/72
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ERG and VE-cadherin expression in E9.5 and E12.5 embryos Figure 3
ERG and VE-cadherin expression in E9.5 and E12.5 embryos. (A)Transverse section of an E9.5 embryo (left). Right 
hand 4-part panel demonstrates ERG expression (green), VE-cadherin (red); overlap of ERG and VE-cadherin (lower left) and 
with DAPI staining (lower right). (B) Evaluation of ERG (green) and VE-cadherin (red) expression in sagittal sections of the 
dorsal aorta (E12.5) of the mouse embryo. Co-localization of ERG and VE-cadherin are shown in the lower left hand panel, and 
with DAPI nuclear staining (bottom right panel). The images were obtained with Leica fluorescence microscope at 10× and 40× 
magnification. Scale bars: 70 μm (A) and 40 μm (B).BMC Developmental Biology 2009, 9:72 http://www.biomedcentral.com/1471-213X/9/72
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tions in the expression of a number of transcription fac-
tors as well as EC-restricted genes. Quantitative RT-PCR
was used to evaluate changes in the expression of selected
ETS transcription factors in differentiated ES cells derived
from control and ERG shRNA treated clones. Whereas a
significant reduction in the expression of ERG was
observed, no change in the expression of other Ets factors
was observed (Additional file 12A). We similarly exam-
ined the expression of a number of mesodermal and
hematopoietic markers and did not observe significant
changes in the expression of these markers, with the
exception of the Scl gene where we observed a slight
reduction (Additional file 12B). In contrast, reductions in
several EC-restricted proteins and transcription factors
known to regulate EC-restricted gene expression were
observed (Additional file 12C). Further validation of
some of the putative ERG targets was evaluated by chro-
matin immunoprecipitation (Additional file 13). In addi-
tion to VE-cadherin, we confirmed binding of ERG to
putative ERG binding sites within the proximal promoters
of the Hey2 and endoglin genes.
Evaluation of ERG expression in the developing heart Figure 4
Evaluation of ERG expression in the developing heart. Sagittal sections of E9.5 mouse embryos with DAPI staining (left 
upper panel). High power magnification of the developing cardiac ventricular chamber (upper right) and common atrial cham-
ber. The ventricular chamber is highly trabeculated and expression of the endocardial surface is shown by VE-cadherin staining 
(red). ERG (green) co-localizes with VE-cadherin expressing cells in both the atrium and ventricular chambers. The images 
were obtained with Leica fluorescence microscope at 10× and 40× magnification. Scale bars represent 80 μm and 70 μm (top 
and bottom panel, respectively).BMC Developmental Biology 2009, 9:72 http://www.biomedcentral.com/1471-213X/9/72
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ERG knockdown in ERG shRNA treated EB Figure 5
ERG knockdown in ERG shRNA treated EB. (A) Four different ERG shRNA sequences were used for transduction and 
expression in ES cells prior to EB differentiation. A scrambled nucleotide sequence was used as a control. (B) Evaluation of 
ERG expression by Q-RT-PCR in EBs at day 8 using lentivirally delivered control, and ERG shRNAs (lentivirally delivered 
sequences #1-4 were used to generate ERGshRNA ES cell clones #1-4 respectively). Expression levels are shown as a percent-
age of control shRNA treated cells Error bars indicate means +/- S.D. (n = 4). (C) Evaluation of ERG expression in differentiat-
ing control and ERG shRNA treated ES cells by Western blot analysis. (D) Immunohistochemical analysis of ERG (green), VE-
cadherin (red), and nuclear staining DAPI (blue) in EBs from control and ERG shRNA clones # 3 and 4 at day 10 and day 8 (# 
3) The images were obtained using Leica fluorescence microscope at 40× magnification. Scale bar represents 100 μm. (E). Eval-
uation of VEGF-R2 expression in ERG shRNA (#3 and #4), or control shRNA treated ES cells by flow cytometry at 3 and 6 
days after differentiation.BMC Developmental Biology 2009, 9:72 http://www.biomedcentral.com/1471-213X/9/72
Page 9 of 14
(page number not for citation purposes)
Discussion
The results of several recent studies point towards an
emerging role for ERG as a transcriptional regulator of EC-
restricted genes [17-20]. The findings of our study support
a unique role for the ETS factor ERG as a transcriptional
regulator of endothelial differentiation. ERG expression
was first detected in a sub-population of VEGF-R2+
expressing cells that co-express VE-cadherin, and closely
correlates with the expression of VE-cadherin during ES
cell differentiation. Inhibition of ERG expression, how-
ever, did not alter the number of VEGF-R2 expressing cells
just prior to their differentiation along the endothelial
and hematopoietic lineages suggesting that ERG is not
required for the formation of the hemangioblast or
hematopoiesis. A recent genome-wide analysis of ETS fac-
tors in zebrafish identified three members of the ETS tran-
scription factor family, including ERG, Fli-1, and ETSRP,
as playing a role in hemangioblast differentiation and
angiogenesis [25]. Of these ETS family members, ETSRP
was expressed earliest and required for hemangioblast for-
mation. Similarly, mice that have a mutation in the ER71,
the homologue of ETSRP exhibit defects in hematopoiesis
and endothelial differentiation [26]. In contrast, neither
knockdown of ERG or Fli-1 in zebrafish led to abnormal-
ities in hemangioblast formation, which is consistent with
our findings in murine ES cells.
We observed a very close correlation of ERG and VE-cad-
herin expression in the EB throughout ES cell differentia-
tion. ERG expression also closely correlates with VE-
cadherin expression during embryonic vascular develop-
ment. ERG has previously been shown to regulate the VE-
cadherin gene in ECs [22]. Targeted disruption of VE-cad-
herin prevented the formation of vessel-like structures in
embryoid bodies [27]. During mouse development, defi-
ciency of VE-cadherin did not affect the initial assembly of
a vascular plexus but was associated with impaired vascu-
lar remodeling and maturation [24]. Knockdown of ERG
expression not only affected vascular structure formation
in embryoid body, but was also associated with a marked
reduction in the number of EC. This suggests that ERG
must regulate additional genes involved in the formation
of EC. Similar knockdown studies were conducted in
zebrafish using morpholino oligonucleotides (MO). MOs
directed against ERG resulted in hemorrhagic defects in
the brain between days 2.5 and 3.0 without any obvious
morphological defects [25]. Similar defects were observed
with MOs directed against Fli-1. Double knockdown of
ERG and Fli-1 led to more severe developmental defects
with disorganization of the intersomatic vessels. In con-
trast to our study, knockdown of ERG in zebrafish was not
associated with a significant reduction in the number of
ECs that would be expected to be associated with more
pronounced defects in vascular development. One possi-
ble explanation for the differences observed is that the
MOs may have reduced, but not abolished the levels of
ERG to a point where sufficient levels of the ERG protein
were present to promote EC differentiation but not later
stages of vascular development. Alternatively, changes in
the function of selected ETS family members may have
occurred over the course of evolution, with ERG playing a
more dominant role in murine vascular development
than in zebrafish.
One of the earliest known markers of hematopoiesis is
CD41 (glycoprotein IIb) [28]. While CD41 expressing ES
cells are capable of contributing to multiple hematopoi-
etic lineages, they cannot differentiate into ECs. We did
not observe significant expression of ERG in VEGF-R2+
cells expressing CD41. Furthermore, ERG knockdown was
not associated with reductions in hematopoietic progeni-
tor cells. This is in contrast to recent reports supporting a
role for ERG in hematopoiesis [29]. A missense mutation
associated with the alteration of one amino acid in the
ERG DNA binding domain (Mld2) was associated with
marked defects in hematopoiesis due to reductions in
transactivation but no change in DNA binding affinity.
The results of this study contrast with our knockdown
studies, and might be explained by the fact that a muta-
tion in ERG could result in the formation of a dominant-
negative protein with altered affinity for different target
Table 1: FACS analysis of control and ERG shRNA treated embryoid bodies.
Day 6 Day 8 Day 10
Control ERG ShRNA  Control ERG ShRNA Control ERG ShRNA
CD 41 1.4% 1.9% 2.5% 2.1% 2.3% 5.5%
CD 45 0.8% 1.3% 0.7% 0.5% 2.4% 3.1%
VE-Cadherin 5.8% 1.5% 19.3% 10.4% 26.8% 5.7%
Endoglin 23.6% 1.8% 26.0% 19.3% 25.7% 10.2%
Tie2 10.5% 9.3% 19.6% 17.4% 20.6% 13.2%
VEGF-R1 26.6% 25.9% 34.9% 25.4% 21.8% 16.4%
Flow cytometric analysis of control and ERG shRNA treated EBs at different time points (day 6, 8, 10) using antibodies directed against endothelial 
(VE-cadherin, endoglin, Tie2, and VEGF-R1) and hematopoietic (CD41, CD45) cell surface markers.BMC Developmental Biology 2009, 9:72 http://www.biomedcentral.com/1471-213X/9/72
Page 10 of 14
(page number not for citation purposes)
ERG target genes in VEGF-R2+ ES cells Figure 6
ERG target genes in VEGF-R2+ ES cells. (A) Normalized microarray expression values for ERG in VEGF-R2+ cells sorted 
from ERG shRNA or control cells 2, 3, and 4 days after differentiation. (B) Heat map of a subset of genes that are significantly 
differentially downregulated after 3 days and 4 days in ERG shRNA versus control ES cells. In the heatmaps, rows represent 
genes and columns represent samples, ordered as control and shRNA treated. Genes are clustered using row-normalized sig-
nal values which are mapped to the [-1,1] interval. Transcription factors are shown in blue. All other genes are shown in black. 
Signal values are color-coded so that red and green represent high and low expression values, respectively.BMC Developmental Biology 2009, 9:72 http://www.biomedcentral.com/1471-213X/9/72
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genes or changes in the affinity of ERG for different inter-
acting proteins.
One of the major downstream targets of ERG is VE-cad-
herin. Within the developing embryo there are also tem-
poral changes in the expression of VE-cadherin in
hematopoietic stem cells (HSCs) [30]. Whereas VE-cad-
herin is expressed in HSCs within the AGM of embryos at
day 11.5, and in the yolk sac at day 12.5, there is marked
down regulation of VE-cadherin expression during fetal
liver colonization and complete loss in HSCs with the
adult bone marrow formation, suggesting that although a
subset of HSCs may be derived from a common bipotent
precursor population, expression of endothelial markers
is not required for maintenance of long-term HSC progen-
itor cells at later stages of embryonic development or in
the adult. Previous studies have demonstrated that VEGF-
R2+/CD144+ isolated from mouse embryos 7.5 to 9.5
days post coitum (dpc) or from human ES cells that are
CD45 negative but are capable of differentiating along the
endothelial and hematopoietic lineages [31,32].
Although VE-cadherin expressing cells are capable of dif-
ferentiating into hematopoietic cells, VE-cadherin nega-
tive cells exhibited a 15-20 fold greater potential of
promoting definitive hematopoiesis than did those
expressing VE-cadherin [33]. Targeted disruption of the
VE-cadherin gene did not significantly impair hematopoi-
esis, with similar numbers of erythroid, myeloid, and
mixed hematopoietic progenitor cells in E8.5 embryos
compared to wild type controls [24]. This would support
the overall concept of a "hemogenic" endothelium, but
with a predominant mechanism of hematopoietic differ-
entiation being independent of EC differentiation.
ERG is among a very few number of transcription factors
that exhibit an EC-restricted expression pattern. For exam-
ple, Vezf1 is a zinc finger transcription factor that contrib-
utes to vascular remodeling and the development of both
the vascular and lymphatic endothelium [34]. The home-
obox transcription factor Hex is expressed at the heman-
gioblast stage and contributes to the hematopoietic and
endothelial lineages [34]. Another family of transcription
factors belonging to the FoxO subset of forkhead tran-
scription factors are expressed in ECs and function as tran-
scriptional regulators of angiogenic growth factors and
vascular stabilization [35]. Selected transcription factors
have also been identified that regulate later stages of
endothelial differentiation, into arterial (Hey1 and Hey2),
venous (COUP-TFII), and lymphatic endothelium (Prox-
1) [35]. ERG shRNA was associated with significant
decreases in the expression of Vezf1, Hey1, and Hey2,
with confirmation of at least one of these transcription
factors, Hey2, as being a direct target of ERG as demon-
strated by ChIP. In contrast, transcription factors known
to be critical regulators of hematopoiesis, including
Runx1 and HoxB4, were not significantly altered by
knockdown of ERG. In summary, the results of our study
provide strong evidence for a critical role for ERG as a
transcriptional regulator of early EC differentiation that
does not affect hematopoiesis or hemangioblast develop-
ment.
Conclusion
The results of our study demonstrate that ERG regulates
the expression of a number of EC-restricted genes during
ES cell differentiation. Knockdown of ERG is associated
with a significant reduction in the formation of vascular
structures in developing embryoid bodies and the number
of endothelial cells, that may have important implications
for the role of ERG in vascular development during mouse
embryogenesis. ERG does not appear to be required for
the development of hematopoietic precursor cells during
ES cell differentiation. ERG may therefore play a unique
role as a transcriptional regulator of EC differentiation
that is distinct from hematopoiesis.
Methods (abbreviated; see Supplemental methods, 
additional file 14)
ES culture
CCE mouse embryonic stem cells (ATCC) were main-
tained on irradiated primary mouse embryonic fibrob-
lasts (MEFs) (Chemicon) in knockout KO-DMEM
(Invitrogen/Gibco-BRL) supplemented with ES-cell grade
15% fetal bovine serum (Hyclone, Logan, UT), penicillin/
streptomycin 1% (Invitrogen/Gibco-BRL), L-glutamine 2
mM (Invitrogen/Gibco-BRL), non-essential amino acids
0.1 mM, nucleosides 0.1 mM, 2-mercaptoethanol 0.1 mM
(Sigma, St. Louis, MO), and ESGRO leukemia inhibitory
factor (LIF) 1000 units/ml (Sigma). ES cells were grown
on MEFs in the presence of LIF to maintain their undiffer-
entiated state for 48 hours.
Embryoid Body Model
The embryoid body is a widely accepted model of differ-
entiation that recapitulates many of the early events of
embryogenesis including hematopoiesis and endothelial
differentiation. Prior to differentiation, the ES cells are
removed from the feeder cells by trypsinization, mixed to
a single cell suspension and plated at density of 2 × 106
cells/10 cm dish (Fisher Scientific) containing KO-DMEM
growth media without LIF to promote ES differentiation.
Real Time PCR
SYBR Green I-based real-time PCR was carried out on an
Opticon Monitor (MJ Research, Inc., Waltham, MA). All
PCR mixtures contained PCR buffer with final concentra-
tion: 10 mM Tris-HCl (pH 9.0), 50 mM KCl, 2 mM
MgCl2, and 0.1% TritonX-100), 250 μM deoxy-NTP
(Roche), 0.5 μM of each PCR primer, 0.5× SYBR Green I,
5% DMSO, and 1 U Taq DNA polymerase with 2 μl cDNA
in a 25 μl final volume of reaction mix. For each run, serial
dilutions of human GAPDH plasmids were used as stand-BMC Developmental Biology 2009, 9:72 http://www.biomedcentral.com/1471-213X/9/72
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ards for quantitative measurement of the amount of
amplified cDNA and GAPDH primers were used to meas-
ure the amount of GAPDH cDNA. For normalization of
each sample, copy number was determined/10,000 copies
of GAPDH in the sample.
Lentiviral shRNA for knockdown studies in ES cells
Lentivirus encoding the shRNA directed against particular
gene targets of interest (Sigma) and polybrene (8 μg/ml;
Sigma, Cat.# H9268) was added to the ES cells and incu-
bated for 4 hours, after which 1 ml of ES media was added
to the infected cells. Stable clones were puromycin
selected and expanded.
Flow cytometry and Fluorescence-activated cell sorting (FACS)
EBs were washed twice in PBS (without Ca2+ and Mg2 and
broken down into a single cell suspension. Flow cytome-
try runs and FACS sorting were performed on the FX5000
Flow Cytometer/FACS sorter at the Beth Israel Medical
Center Flow Cytometry Facility, using the CXP analysis
software.
Microarray analysis
For transcriptional profiling, the mouse genome 430 2.0
Affymetrix GeneChip, containing more than 45,000 tran-
scripts were used. RNAs for the microarray experiments
were obtained in duplicates from two separately con-
ducted experiments using the murine embryonic stem
cells.
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Additional material
Additional file 1
Analysis of ERG and Ter119 expression by flow cytometry during ES cell 
differentiation. Expression of ERG (FITC labeled) and Ter119 (PE-
labeled) was analyzed using the flow-cytometry technique in day 8.5, 
10.5 and 12.5 EBs. Flow-cytometry diagrams show expression of the two 
markers on clearly two distinct cell populations (Ter199 population 
migrating along the y-axis, while the ERG population shifts along the x-
axis).
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
213X-9-72-S1.PDF]
Additional file 2
Evaluation of ERG expression by confocal microscopy. EB sections were 
stained for ERG (green), VE-cadherin (red), and nuclei (blue) and visu-
alized by laser-scanning confocal microscopy. A-C. ERG (A), VE-cadherin 
(B) and merge of all three stains is depicted in (C). (D) Depicts a subre-
gion as indicated in panel C. (E-G) These panels depict a subregion of 
panel D as indicated, and show ERG (E) and nuclei (G) alone or merged 
(F). Note that ERG staining is largely coincidental with nuclei. Scale bar 
= 100 μm in panel A; = 20 μm in panel D, and; = 5 μm in panel G.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
213X-9-72-S2.PDF]
Additional file 3
Fluorescence microscopy evaluation of ERG expression with endoglin and 
CD45 in day 10 EBs. Panel (A) and (B) show double fluorescence immu-
nostaining of ERG (green) with the endothelial-specific endoglin (red) 
and hematopoietic cell marker CD45 (red), respectively. Panel (A) dem-
onstrates ERG co-localization with endoglin in the endothelial cells that 
line the vascular channel walls of the cystic EBs, while in panel (B), 
CD45 expression is seen in hematopoietic progenitor cells that bud off 
from the channel's wall and migrate towards the center of the vascular 
channel lumen. Scale bar = 100 μm.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
213X-9-72-S3.PDF]
Additional file 4
ERG and VEGF-R2 expression in E7.5 embryo. (A-B)Serial sections of 
mouse E7.5 embryo showing expression of ERG and VEGF-R2 in a similar 
subset of cells in the blood islands, respectively. Arrowheads indicate non-
specific staining of the antibodies. (C, D) Higher magnification of (A, B). 
Arrows point to the cells of the blood islands that express ERG within the 
nucleus (C) and VEGF-R2 on the surface (D) al, allantois; am, amnion; 
bi, blood island; m, maternal decidua. Scale bars: 50 μm
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
213X-9-72-S4.PDF]
Additional file 5
ERG expression in intersomatic blood vessels in the developing embryo at 
E12.5. Sagittal sections of frozen mouse embryo at E12.5 (far left image) 
fluorescence stained with DAPI nuclear stain (blue). The inset box points 
to the developing somite region in the mouse embryo, which is 20× mag-
nified in the middle column (a, c and e) and 40× magnified in the far 
right column (b, d and f). Both columns demonstrate ERG co-localization 
(a, b, green) with the endothelial-specific VE-cadherin (c, d, red) in the 
developing intersomatic blood vessels. Image (e) and (f) are overlays with 
DAPI (blue) which outlines the general tissue morphology. Images were 
obtained with Leica fluorescent microscope. Scale bars: 80 μm (a, c and 
e) and 30 μm (b, d and f).
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
213X-9-72-S5.PDF]BMC Developmental Biology 2009, 9:72 http://www.biomedcentral.com/1471-213X/9/72
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Additional file 6
ERG expression in the aorta-gonado-mesonephros (AGM) region of the 
developing mouse embryo at E12.5. (A) Sagittal section of a frozen mouse 
embryo at E12.5, fluorescence stained with DAPI nuclear stain (blue). 
The inset boxes 1 and 2 outline the AGM and umbilical cord remnant, 
respectively, in the E12.5 mouse embryo. Panel (B) represents magnifica-
tion of inset 1 and shows ERG co-expression (a, green) with the endothe-
lial-specific VE-cadherin (b, red) in the developing vasculature of the 
embryonic AGM region. (c) is a merged image of (a) and (b), while (d) 
is an overlay with DAPI (blue). The thin arrows in (c) point to the mes-
onephric blood vessels of the AGM region, while the thick arrow in (d) 
points to the dorsal (posterior) root ganglion of AGM. Images in panel (A) 
and (B) were taken with Leica fluorescent microscope at 10× and 20× 
magnification, respectively. Scale bar = 30 μm.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
213X-9-72-S6.PDF]
Additional file 7
ERG expression in the umbilical cord of day E12.5 embryo. (A) Magnifi-
cation of inset box 2 from Additional file 6 showing the DAPI stained rem-
nants of the placenta and umbilical cord vein, respectively. ERG (green, a 
and e) also co-localizes with VE-cadherin (red, b and f) in the umbilical 
cord arteries (panel B) and umbilical cord vein (panel C). Scale bar rep-
resents 90 μm.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
213X-9-72-S7.PDF]
Additional file 8
Effect of ERG knockdown on its direct targets by flow cytometry analysis 
at different time points. Flow cytometry analysis of the ERG target genes 
VE-cadherin and endoglin during EB differentiation in ERG shRNA con-
trol and shRNA #4 cells. Each flow cytometry diagram is labeled with PE-
conjugated antigen-specific Ab that migrates along the y-axis.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
213X-9-72-S8.PDF]
Additional file 9
The effect of ERG knockdown on in-vitro vascular sprout formation on dif-
ferentiating EB's. (A). Comparison of mean total length of vascular 
sprouts in control and ERG ShRNA knockdown EB's. Error bars indicate 
means +/- S.D. (n = 2, with 50-100 EBs per experiment) (B). Represent-
ative examples of EBs stained with CD31. Scale bar, 100 μm.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
213X-9-72-S9.PDF]
Additional file 10
Hematopoietic colony forming assay in control and ERG shRNA treated 
ES cells. (A) Hematopoietic colonies including primitive erythroid colony 
Ery-P (a and b), blast colony forming unit containing definitive erythroid 
progenitors BFU-E (c and d), and colony forming units with granulocytes 
and macrophages CFU-GM (e and f) were formed by both, control shRNA 
ES cells (a, c, and e) and ERG shRNA treated ES cells (b, d, and f), when 
grown on methylcellulose base and in presence of hematopoietic growth 
factors. Images were taken on Nikon light microscope at 10× and 20× 
magnification. (B) Hematopoietic potential of control and ERG shRNA 
treated ES cells. The number of individual colonies (Ery-P, BFU-E, and 
CFU-GM) is expressed as percentage of the total number of colonies for 
each phenotype (control vs. ERG shRNA ES cells). (C) Values used in the 
table represent average number of counted colonies from three individual 
plates (n = 3). Error bars indicate means +/- S.D.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
213X-9-72-S10.PDF]
Additional file 11
List of differentially expressed genes in ERG shRNA versus control ES 
cells. Selected list of genes that are significantly changed after 3 days or 4 
of ES cell differentiation in the control versus ERG shRNA treated cells. 
The Fold change (FC) and Lower Bound of Fold change (LCB) of signif-
icantly changing genes is shown in BOLD.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
213X-9-72-S11.PDF]
Additional file 12
Real-time RT-PCR analysis of control and ERG shRNA treated EBs at day 
4.5. (A) Expression of ETS family of transcription factors in control 
shRNA and ERG shRNA treated EBs at day 4.5. (B) QRT-PCR evalua-
tion of expression of mesodermal and hematopoietic markers in control 
and ERG shRNA treated EBs at day 4.5 of differentiation. (C) Analysis 
of expression of different endothelial-cell specific markers in control and 
ERG shRNA treated EBs at day 4.5. In all three experiments differential 
expression of cell-lineage specific markers in control EBs was compared 
with EBs treated with two different ERG shRNAs: sequence #3 and #4. 
For each molecular marker tested n = 3 and the error bars indicate means 
+/- S.D.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
213X-9-72-S12.PDF]
Additional file 13
Downstream targets of ERG. (A, B, C) Top: Schematic diagram of ERG 
binding sites in VE-cadherin, Hey-2, or Endoglin promoter, respectively. 
The 1.5 kb upstream promoter region of each gene was analyzed in search 
for the potential ERG binding sites indicated with red boxes. The bidirec-
tional arrows marked the target regions for ChIP assays (ChIP1 and/or 
ChIP2). (A, B, C) Bottom: ChIP assay using HUVEC. An ERG polyclo-
nal antibody was used for precipitation. PCR analysis of the input, in the 
absence of ERG antibody (CTR), and in the presence of ERG antibody 
(ERG) after immunoprecipitation (IP) using primers corresponding to 
indicated ERG putative binding sites (ChIP1 and/or ChIP2) of the each 
gene promoter. Molecular weight markers are shown on the left.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
213X-9-72-S13.PDF]BMC Developmental Biology 2009, 9:72 http://www.biomedcentral.com/1471-213X/9/72
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